BridgeBio Pharma (NASDAQ:BBIO) Stock: Insider Maricel Apuli Sells 2,000 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CAO Maricel Apuli sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $72.85, for a total value of $145,700.00. Following the completion of the transaction, the chief accounting officer directly owned 120,687 shares in the company, valued at approximately $8,792,047.95. This represents a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Stock Performance

BBIO opened at $77.89 on Thursday. The stock’s fifty day moving average is $69.95 and its two-hundred day moving average is $72.81. BridgeBio Pharma, Inc. has a 52 week low of $60.55 and a 52 week high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Thursday, October 29th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.12. The business had revenue of $353.17 million for the quarter, compared to analysts’ expectations of $293.47 million. The business’s revenue for the quarter was up 192.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.95) EPS. On average, research analysts anticipate that BridgeBio Pharma, Inc. will post -2.59 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on BBIO shares. Morgan Stanley lifted their price target on shares of BridgeBio Pharma from $87.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Barclays lowered their target price on shares of BridgeBio Pharma from $157.00 to $156.00 and set an “overweight” rating for the company in a report on Wednesday, October 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of BridgeBio Pharma in a report on Monday, October 5th. Mizuho boosted their price objective on shares of BridgeBio Pharma from $96.00 to $110.00 and gave the company an “outperform” rating in a research note on Tuesday, September 1st. Finally, TD Cowen dropped their price objective on BridgeBio Pharma from $110.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, October 30th. Nineteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $104.26.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BBIO. Jupiter Topco LLC acquired a new position in shares of BridgeBio Pharma in the second quarter valued at approximately $1,050,762,000. Janus Henderson Group PLC lifted its holdings in shares of BridgeBio Pharma by 19.8% during the 1st quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock worth $978,608,000 after acquiring an additional 2,178,556 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of BridgeBio Pharma during the 2nd quarter worth $145,663,000. Primecap Management Co. CA purchased a new stake in shares of BridgeBio Pharma during the 2nd quarter worth about $75,670,000. Finally, Squarepoint Ops LLC raised its stake in shares of BridgeBio Pharma by 114.2% in the 2nd quarter. Squarepoint Ops LLC now owns 1,191,732 shares of the company’s stock valued at $88,760,000 after acquiring an additional 635,408 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes.

BridgeBio’s portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms.